Better Buy: Novavax vs. Moderna
Here's a story of two biotechs. Both of them scrambled to develop COVID-19 vaccines last year. One of them, Moderna (NASDAQ: MRNA), ranked as one of the first two companies to win emergency use authorizations for its vaccine in the U.S., the U.K., and Europe. The other drugmaker, Novavax (NASDAQ: NVAX), hasn't reported late-stage results for its COVID-19 vaccine candidate yet.
Which of these two biotech stocks do you think was the bigger winner in 2020? Based only on the facts presented above, you might go with Moderna. However, Novavax actually delivered a staggering return of 2,700% last year -- more than six times greater than Moderna's performance.
What does that indicate about which of these stocks is the better pick now? Nothing. Here's what you'll really need to know to decide between Novavax and Moderna.
Source Fool.com
